RESEARCH MONOGRAPH · KDC-MN-144

Methylphenidate

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

82/100

An established stimulant where the phenethylamine label undersells what the molecule actually does

Methylphenidate is one of the most-prescribed psychoactive medications globally and one of the most-studied. The standard summary is "DAT/NET inhibitor" and that's correct but oversimplified. The blockade of DAT in particular drives most of the cognitive and reinforcing effects. Volkow's PET imaging studies in the 90s and 2000s established that clinical doses occupy roughly 50 to 80 percent of striatal DAT, which puts it in a similar receptor-occupancy range to cocaine but with much slower binding kinetics. The slow onset is part of why the abuse liability profile is lower than cocaine despite similar primary pharmacology.

The d-threo enantiomer (dexmethylphenidate) is essentially all of the active drug; the l-threo enantiomer is largely inactive at DAT. Standard methylphenidate is the racemate, dexmethylphenidate (Focalin) is the purified d-isomer. From a research perspective the enantiomeric purity question matters if you're doing receptor occupancy work.

What we like: among the stimulants, methylphenidate has the best-characterized cognitive effects on working memory, sustained attention, and inhibitory control. The Diamond and Aron lab work on prefrontal function under methylphenidate is good. The dose-response curve is well-mapped, the pharmacokinetics (oral bioavailability around 30 percent, extensive first-pass metabolism via CES1, short half-life of 2 to 3 hours for immediate release) are textbook. As a research tool for DAT pharmacology and prefrontal dopaminergic effects on cognition its hard to beat.

What we dont like: the methylphenidate is to amphetamine what we sometimes wish ADHD pharmacology was simpler about. Amphetamine has additional release effects (VMAT reversal driving DA efflux, partial MAO inhibition) that methylphenidate lacks; methylphenidate has cleaner reuptake-inhibitor pharmacology. They're not interchangeable mechanistically even if the clinical indications overlap.

Mechanism: well-mapped at the transporter level. The downstream effects on prefrontal-striatal circuitry are increasingly well-characterized.

Sourcing: established pharmaceutical, racemic or enantiomerically-pure forms available, research-grade is reliable from major suppliers. Schedule II in the US which has regulatory implications for sourcing.

Established workhorse with cleaner DAT pharmacology than amphetamines.

Evidence: 95
Mechanism: 90
Reliability: 85
Safety: 70
Sourcing: 80
Value: 75
Signal: 75
Staying power: 85

Plain-language summary Intrigue 80 / 100

Methylphenidate, sold as Ritalin and Concerta, is the most prescribed ADHD medication. It blocks dopamine and norepinephrine transporters but also produces some monoamine release. Schedule II in the US. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Phenethylamine DAT/NET inhibitor

A phenethylamine-class DAT and NET inhibitor FDA-approved as Ritalin and Concerta for ADHD.

Abstract

Methylphenidate (Ritalin, Concerta; CAS 113-45-1; molecular formula C14H19NO2; molecular weight 233.31) is a phenethylamine-class psychostimulant first synthesized in 1944 and approved by the FDA in 1955. The compound is a primary clinical treatment for ADHD and is also used for narcolepsy. Mechanism is dopamine and norepinephrine transporter inhibition (DAT, NET); unlike amphetamine-class stimulants, methylphenidate does not produce significant monoamine release through transporter inversion. The (R,R)-enantiomer (dexmethylphenidate) carries most of the activity. Pharmacokinetics: plasma half-life 2 to 4 hours (immediate release); extended-release formulations span 8 to 12 hours. Schedule II in the United States.

Mechanism of action

DAT and NET reuptake inhibitor; minimal monoamine release. (R,R)-enantiomer is the active component.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Volkow ND, et al. Effects of methylphenidate on the dopamine system. J Pharmacol Exp Ther 1995.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-144

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Methylphenidate

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs